AI’s Trillion-Dollar Heart: Investing in CVD Prevention Startups

The landscape of cardiovascular disease prevention is undergoing a profound transformation, driven by the accelerating integration of artificial intelligence. As the world’s leading cause of mortality, the economic and human burden of cardiovascular disease (CVD) demands innovative solutions, and AI is proving to be a critical lever in shifting from reactive treatment to proactive prevention. For investors, this convergence represents a multi-billion dollar opportunity, ripe for identifying the next generation of category-defining companies.

The New Frontier: Why AI in Preventative Cardiology is a Multi-Billion Dollar Opportunity

The “why now” for AI in preventative cardiology is compelling. We are at an inflection point where massive, previously disparate datasets, from electronic health records (EHRs) and medical imaging to genomics and wearables, are becoming computationally tractable. Coupled with advancements in AI/ML algorithms and a healthcare system increasingly shifting towards value-based care models, the stage is set for AI to fundamentally reshape how we identify, stratify, and intervene in cardiovascular risk. This isn’t merely an incremental technological improvement; it’s a paradigm shift towards precision prevention. The total addressable market (TAM) for AI in cardiology is projected to grow substantially, with estimates placing it at approximately $14.8 billion by 2033, up from roughly $1.7 billion in 2025 Grand View Research AI in Cardiology Market Report. This explosive growth underscores the market’s recognition of AI’s potential to address the staggering economic burden of preventable CVD, which costs the U.S. healthcare system hundreds of billions annually AHA statistics on CVD economic burden. The ability of AI to move beyond traditional, often insufficient, risk factor assessments to more granular, personalized insights offers a clear path to improved patient outcomes and significant cost savings, making it a critical area for strategic investment.

Methodology: How We Identify True Momentum

To answer the investor prompt, “Who are the fastest-growing AI startups in cardiovascular prevention?” we employ a rigorous, data-driven cohort analysis. Our methodology moves beyond anecdotal evidence or media hype, focusing instead on leading growth indicators relevant to both early-stage and growth-stage investors. We are not simply listing companies; we are scoring them based on a weighted model designed to surface true momentum and strategic positioning. Our ranking is derived from three core metrics, each providing a distinct lens into a company’s growth trajectory and market validation: 1) Total capital raised in the last 24 months, reflecting investor confidence and operational runway; 2) 12-month percentage headcount growth, indicating scaling operations and talent acquisition; and 3) Number of active or recently completed clinical trials listed on ClinicalTrials.gov, demonstrating a commitment to clinical validation and regulatory de-risking. Capital data is primarily sourced from PitchBook and Crunchbase, while headcount growth is tracked via LinkedIn Sales Navigator and Growjo. Clinical trial data is directly extracted from ClinicalTrials.gov. This multi-faceted approach provides a holistic view of a company’s health and growth potential, crucial for investors seeking to identify sustainable innovators rather than fleeting trends.

The Ranking: The Fastest-Growing AI Prevention Startups

This section presents our flagship ranking of the fastest-growing AI startups in cardiovascular prevention, based on our transparent methodology. Each company profile details their unique value proposition, strategic moat, market traction, and the growth signals that position them as leaders in this burgeoning sector.

1. Cleerly: The Leader in AI-Powered Coronary Analysis

Cleerly stands out as a category leader, fundamentally shifting the paradigm of cardiovascular prevention from indirect risk factor assessment to direct, non-invasive coronary plaque analysis. Their AI-driven solution analyzes computed tomography angiography (CTA) scans to quantify and characterize atherosclerosis, providing physicians with unprecedented visibility into the actual presence and severity of coronary artery disease (CAD), even before symptoms manifest. This approach moves beyond traditional risk scores, which often miss a significant portion of individuals at high risk. The company’s growth trajectory is robust, underpinned by significant investor backing. Cleerly secured a $106 million Series C extension funding round in December 2024, bringing their total capital raised to $578 million. This substantial investment reflects strong confidence in their technology and market potential. Their headcount growth has been aggressive, expanding by approximately 35% in the last year, reaching 354 employees as of May 2026, signaling rapid operational scaling to meet demand. Cleerly’s commitment to clinical validation is evident through their active clinical trial pipeline, including studies focused on improving patient outcomes and demonstrating cost-effectiveness in diverse populations. Their FDA 510(k) clearances for various components of their AI platform, including Cleerly ISCHEMIA in January 2024, underscore their regulatory maturity and readiness for widespread adoption. Cleerly’s data moat, built on a vast repository of annotated CTA images, creates a significant barrier to entry for competitors, solidifying their position as a key innovator in precision prevention.

2. Hello Heart: Personalizing Cardiac Risk Management via healthcare AI platforms

Hello Heart has established itself as a frontrunner in healthcare AI solutions for cardiovascular prevention, particularly focusing on hypertension and lipid management. Their AI-powered mobile application empowers individuals to track, understand, and manage their cardiac health through personalized insights and behavioral interventions. By integrating data from smart blood pressure cuffs and other health trackers, Hello Heart’s platform provides actionable feedback and support, driving sustained engagement and improved health outcomes. The company’s growth is fueled by a clear value proposition for employers and health plans seeking to reduce cardiovascular events and associated costs. Hello Heart raised a $70 million Series D round in May 2022, bringing their total funding to $138 million. This capital infusion has supported a year-over-year headcount growth of 24.1% as of March 2026, reaching 690 employees, demonstrating rapid expansion of their engineering, clinical, and commercial teams. While not conducting traditional drug trials, Hello Heart has published extensive real-world evidence (RWE) demonstrating significant reductions in blood pressure and improved medication adherence among its users Hello Heart Clinical Validation Studies. This RWE, crucial for payer reimbursement and enterprise adoption, acts as a powerful clinical validation. Their FDA-cleared Monitor, delivering a highly scalable and engaging platform, positions them uniquely in the preventative cardiology landscape.

3. Anumana: Leveraging ECG-AI for Early Disease Detection

Anumana, an AI-native company born from a strategic collaboration between nference and Mayo Clinic, is pioneering the use of artificial intelligence to extract novel insights from standard electrocardiograms (ECGs) for early disease detection. Their technology aims to identify asymptomatic cardiovascular conditions such as low ejection fraction, pulmonary hypertension, and hypertrophic cardiomyopathy, often years before clinical presentation. This proactive identification enables earlier intervention, potentially averting severe outcomes. Anumana’s strong ties to Mayo Clinic provide an unparalleled data moat and clinical validation pathway. The company closed a Series C financing round in April 2025, with Boston Scientific Corporation joining as a new investor, contributing to a total raised of $185 million. Anumana has 163 employees. A critical differentiator for Anumana is their progress in securing Category III CPT codes (0764T and 0765T) for their ECG-AI algorithms, effective January 1, 2023 Anumana CPT Code Information. This achievement de-risks a major hurdle for AI-driven diagnostics. Their clinical trial pipeline includes studies validating the accuracy and clinical utility of their various AI models, positioning them to become a standard of care for proactive cardiovascular screening.

Conclusion

The innovators in cardiovascular prevention are not just building better technology; they are building better pathways to health. Cleerly, Hello Heart, and Anumana exemplify the dynamism and potential within this sector, each tackling critical unmet needs with AI-driven solutions that promise to redefine early detection and proactive management. For investors, understanding the nuanced growth drivers, from clinical validation and regulatory strategy to market adoption and data moats, is paramount to identifying the companies poised for long-term success.

3 Key Investor Takeaways:

• Clinical Validation is King: Beyond impressive algorithms, companies demonstrating robust clinical trial pipelines, real-world evidence, and regulatory clearances (510(k), De Novo) are best positioned for commercial scale and reimbursement. This signals a reduced regulatory and adoption risk.
• Data Moats and AI-Native Architectures: Companies with proprietary, large-scale, and diverse datasets, coupled with an AI-native product and business model, possess a significant competitive advantage. This makes their solutions difficult to replicate and improves model performance over time, mitigating algorithmic drift.
• Reimbursement Strategy is Non-Negotiable: Investment in companies actively pursuing CPT codes, NTAP eligibility, or clear value-based care contracts indicates a sophisticated understanding of the healthcare economic landscape, critical for sustainable revenue generation and market penetration.